News

Packaged snacks company Mondelez (NASDAQ:MDLZ) met Wall Street’s revenue expectations in Q1 CY2025, but sales were flat year on year at $9.31 billion. Its non-GAAP profit of $0.74 per share was 12.2% above analysts’ consensus estimates.

Despite the recent rebound, President Trump's first 100 days in office have been marked by extreme volatility.

Hotel and casino entertainment company Caesars Entertainment (NASDAQ:CZR) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 1.9% year on year to $2.79 billion. Its GAAP loss of $0.54 per share was significantly below analysts’ consensus estimates.

Communications chips maker Qorvo (NASDAQ: QRVO) reported Q1 CY2025 results topping the market’s revenue expectations, but sales fell by 7.6% year on year to $869.5 million. Guidance for next quarter’s revenue was optimistic at $775 million at the midpoint, 2.4% above analysts’ estimates. Its non-GAAP profit of $1.42 per share was 41.6% above analysts’ consensus estimates.

Communications chips maker Qorvo (NASDAQ: QRVO) reported Q1 CY2025 results topping the market’s revenue expectations, but sales fell by 7.6% year on year to $869.5 million. Guidance for next quarter’s revenue was optimistic at $775 million at the midpoint, 2.4% above analysts’ estimates. Its non-GAAP profit of $1.42 per share was 41.6% above analysts’ consensus estimates.

Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 132% in the afternoon session after the company announced plans to make it easier for its members to access Eli Lilly's FDA-approved weight loss drug Zepbound. Given the success of weight loss drugs with regulatory approval and the crackdown on knock-offs, expanding the distribution of Zepbound should accelerate adoption. Additionally, companies such as WeightWatchers should benefit from increased sales volume and greater cust

Shares of personal wellness company WeightWatchers (NASDAQ:WW) jumped 132% in the afternoon session after the company announced plans to make it easier for its members to access Eli Lilly's FDA-approved weight loss drug Zepbound. Given the success of weight loss drugs with regulatory approval and the crackdown on knock-offs, expanding the distribution of Zepbound should accelerate adoption. Additionally, companies such as WeightWatchers should benefit from increased sales volume and greater cust